期刊文献+

沙美特罗/氟替卡松联合吸入治疗慢性阻塞性肺疾病急性加重期患者的疗效分析 被引量:3

Effect of inhaled salmeterol/fluticasone in the treatment of acute exacerbations of chronic obstructive pulmonary disease
下载PDF
导出
摘要 目的探讨吸入沙美特罗/氟替卡松对慢性阻塞性肺疾病急性加重期患者的疗效。方法慢性阻塞性肺疾病急性加重期患者46例,全部病例入组前1个月无使用过任何剂型的激素、β受体激动剂、抗胆碱药,无氧疗史。随机分成两组,每组23例,疗程15 d。舒利迭组吸入沙美特罗/氟替卡松;丙酸氟替卡松组吸入丙酸氟替卡松。两组患者其他治疗均按常规治疗。观察两组患者在治疗前后的疗效、肺功能、圣-乔治呼吸问卷(SGRQ)评分和不良反应。结果在治疗结束时,两组治疗效果比较,差异无统计学意义(P>0.05)。舒利迭组的第1秒用力呼气量占预计值百分比(FEV1/预计值)和第1秒用力呼气量占用力肺活量的百分比(FEV1/FFVC)、SGRQ评分(包括呼吸症状、活动能力、疾病影响、SGRQ总分)较治疗前有不同程度的改善(P<0.05),与丙酸氟替卡松组比较差异明显,差异有统计学意义(P<0.05)。丙酸氟替卡松组FEV1/预计值和FEV1/FVC治疗前后差异不明显(P>0.05),SGRQ评分中呼吸症状在治疗前后有明显差异(P<0.05);活动能力、疾病影响、SGRQ总分治疗前后差异不明显,无统计学意义(P>0.05)。结论沙美特罗/氟替卡松联合吸入是治疗慢性阻塞性肺疾病急性加重期安全有效的方法。 Objective To evaluate the effect of inhaled salmeterol/fluticasone in the treatment of patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). Methods Sixty - nine patients with acute exacerbations of COPD who hadnt received cortieoste- roid, β - receptor agonist, anticholine drugs and oxygen therapy for one month were randomly divided into three groups with 23 patients in each group. In addition to routine treatment, seretide group, fluticasone propinate group and salmeterol group received inhaled fluticasone propinate/sal- meterol, inhaled flutieasone propinate and inhaled sahneterol respectively for 15 days. Results At the end of the therapy, there was no statistic difference in treatment efficacy among the three groups. The values of FEV1/predictive value and FEV1/FVC, and SGRQ score ( including total, activity, impacts and symptoms domains) in seretide group increased in different extent than the baseline values ( P 〈0.05). FEV1/predictive value and FEV1/FVC were not different before and after treatment in fluticasone propinate group and salmeteral group ( P 〉 0.05 ), but respirato- ry symptom scores were evidently different ( P 〈 0. 05 ) ; there were no apparent difference after treatment in the activity, impacts and the total scores of SGRQ ( P 〉 0.05 ). Conclusion The treatment of salmeterol plus flutieasone inhalation is safe and effective for the treatment of acute exacerbations of COPD.
出处 《临床和实验医学杂志》 2009年第4期7-8,共2页 Journal of Clinical and Experimental Medicine
关键词 慢性阻塞性肺疾病 急性加重期 沙美特罗/氟替卡松吸入治疗 Chronic obstructive pulmonary disease Exacerbation Salmeterol/fluticasone Inhalation therapy
  • 相关文献

参考文献1

共引文献1845

同被引文献27

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8240
  • 2慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华内科杂志,2007,46(3):254-261. 被引量:1795
  • 3Bames P J. The pharmacological properties of tiotropium[J]. Chest, 2000,117 : 63-66. 被引量:1
  • 4Casaburi R, Mahler D A,Jones P W, et al. Long time evalua- tion of once-daily inhaled tiotropium in chronic obstractive pul- monary disease[J]. Eur Respir, 2002,19 (2) : 217-224. 被引量:1
  • 5Tashkin D P,Celli B,Sonn S,et al. A 4-year trial of tiotropiura in chronic obstructive pulmonary disease[J]. N Engl J Med, 2008,359(5) : 1543-1554. 被引量:1
  • 6The TORCH Study Group. The TORCH(Towardsa Revolu- tion in COPD Health)survival study protocol[J]. Eur Respir, 2004,24:206-210. 被引量:1
  • 7Johnson M, Rennard S. Alternative inechanisms for long-acting beta(2)-adrenergic agonistas in COPD[J]. Chest, 2001,120: 258-270. 被引量:1
  • 8Singh D, Blooks J, Hagan G, et al. Superiority of “triple" ther- apy with salmeterol/flutieasone propionate and tiotropium bromide versus individual components in modlerate to severe COPD[J].Thorax, 2008,63(7) : 592-598. 被引量:1
  • 9CalverleyMA, And erson JA, Celli B, et al. Salmeterol and flutica- sone propionate and survival in chronic obstructive pulmonary dis- ease[J]. N Engl JM ed, 2007, 356(8) :775 -789. 被引量:1
  • 10Singh S, Am in AV, Loke YK. Long-term use of inhaled cortieoste- roids and the risk of pneumonia in chronic obstruetive pulmonary disease: ameta- analys is[J]. Arch In teruM ed, 2009, 169(3) : 219 -229. 被引量:1

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部